Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

41.85USD
22 Mar 2019
Change (% chg)

$-0.50 (-1.18%)
Prev Close
$42.35
Open
$42.28
Day's High
$42.62
Day's Low
$41.83
Volume
6,577,097
Avg. Vol
8,330,375
52-wk High
$46.46
52-wk Low
$34.32

Latest Key Developments (Source: Significant Developments)

Zenith Epigenetics Gains U.S. FDA Clearance Of Investigational New Drug Application For ZEN-3694 In TNBC Program
Monday, 18 Mar 2019 

March 18 (Reuters) - Pfizer Inc ::ZENITH EPIGENETICS ANNOUNCES U.S. FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR ZEN-3694 IN TNBC PROGRAM.ZENITH EPIGENETICS LTD - PFIZER / ZENITH TNBC PROGRAM COLLABORATION ON TARGET TO DOSE FIRST PATIENT IN APRIL 2019.  Full Article

Pfizer's I. Read Receives $19.5 Mln Compensation In 2018
Thursday, 14 Mar 2019 

March 14 (Reuters) - Pfizer Inc ::CHAIRMAN & CEO I. READ'S FY 2018 TOTAL COMPENSATION WAS $19.5 MILLION VERSUS $27.9 MILLION IN FY 2017.2018 COMPENSATION OF READ, WHO MOVED FROM HIS ROLE AS CHAIRMAN & CEO TO EXEC CHAIRMAN EFFECTIVE JAN. 1, INCLUDED $7.03 MILLION IN STOCK AWARDS.F. D’AMELIO, CFO'S FY 2018 TOTAL COMPENSATION WAS $7.1 MILLION VERSUS $8.3 MILLION IN FY 2017.SAYS A. BOURLA'S FY 2018 TOTAL COMPENSATION AS CHIEF OPERATING OFFICER WAS $9.9 MILLION VERSUS $8.8 MILLION IN FY 2017 - SEC FILING.M. DOLSTEN'S FY 2018 TOTAL COMPENSATION AS PRESIDENT, WORLDWIDE RESEARCH AND DEVELOPMENT WAS $7.1 MILLION VERSUS $7.7 MILLION IN FY 2017.SAYS J. YOUNG'S FY 2018 TOTAL COMPENSATION AS GROUP PRESIDENT, PFIZER INNOVATIVE HEALTH WAS $7.1 MILLION VERSUS $11.5 MILLION IN FY 2017.SAYS THE 2018 ANNUAL TOTAL COMPENSATION FOR READ WAS ABOUT 244 TIMES THE ANNUAL TOTAL COMPENSATION OF THE MEDIAN-PAID EMPLOYEE.2018 COMPENSATION OF READ ALSO INCLUDED $6.9 MILLION IN OPTION AWARDS & $3 MILLION PERFORMANCE-BASED AWARD.SAYS THE ANNUAL 2018 TOTAL COMPENSATION OF THE MEDIAN-PAID EMPLOYEE WAS $80,011.  Full Article

U.S. FDA Approves Pfizer’S Oncology Biosimilar Trazimera
Monday, 11 Mar 2019 

March 11 (Reuters) - Pfizer Inc ::U.S. FDA APPROVES PFIZER’S ONCOLOGY BIOSIMILAR TRAZIMERA™ (TRASTUZUMAB-QYYP), A BIOSIMILAR TO HERCEPTIN®1.  Full Article

Pfizer Inc's Drug Trazimera Wins FDA Approval- FDA Website
Monday, 11 Mar 2019 

March 11 (Reuters) - Pfizer Inc ::PFIZER INC'S DRUG TRAZIMERA WINS FDA APPROVAL- FDA WEBSITE.  Full Article

New Zealand Commerce Commission Says Received Clearance Application From Glaxosmithkline Seeking Clearance To Buy Consumer Healthcare Business Of Pfizer
Friday, 8 Mar 2019 

March 8 (Reuters) - :NEW ZEALAND COMMERCE COMMISSION - RECEIVED CLEARANCE APPLICATION FROM GLAXOSMITHKLINE SEEKING CLEARANCE TO BUY CONSUMER HEALTHCARE BUSINESS OF PFIZER.  Full Article

Pfizer Prices $5 Billion Debt Offering
Tuesday, 5 Mar 2019 

March 4 (Reuters) - Pfizer Inc ::PFIZER PRICES $5,000,000,000 DEBT OFFERING.PRICING OF A DEBT OFFERING CONSISTING OF $500 MILLION AGGREGATE PRINCIPAL AMOUNT OF 2.800% NOTES DUE 2022.ANNOUNCED PRICING OF A DEBT OFFERING CONSISTING OF $750,000,000 AGGREGATE PRINCIPAL AMOUNT OF 2.950% NOTES DUE 2024.PRICING OF A DEBT OFFERING CONSISTING OF $1.75 BILLION AGGREGATE PRINCIPAL AMOUNT OF 3.450% NOTES DUE 2029.ANNOUNCED THE PRICING OF A DEBT OFFERING CONSISTING OF $750,000,000 AGGREGATE PRINCIPAL AMOUNT OF 3.900% NOTES DUE 2039.PRICING OF A DEBT OFFERING CONSISTING OF $1.25 BILLION AGGREGATE PRINCIPAL AMOUNT OF 4.000% NOTES DUE 2049.PFIZER- INTENDS TO USE NET PROCEEDS FOR GENERAL CORPORATE PURPOSES, INCLUDING REFINANCE, REDEEM OR REPURCHASE EXISTING DEBT, TO REPAY PORTION OF ITS OUTSTANDING COMMERCIAL PAPER.  Full Article

Pfizer Files For Potential, 5-Part Notes Offering; Size Not Disclosed
Monday, 4 Mar 2019 

March 4 (Reuters) - Pfizer Inc ::PFIZER INC FILES FOR POTENTIAL, 5-PART NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

BioXcel Therapeutics Announces Addition Of Merck KGaA, Darmstadt, Germany, And Pfizer To Clinical Collaboration With Nektar
Monday, 4 Mar 2019 

March 4 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES ADDITION OF MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER TO CLINICAL COLLABORATION WITH NEKTAR FOR DEVELOPMENT OF TRIPLE-COMBINATION THERAPY IN PANCREATIC CANCER.BIOXCEL THERAPEUTICS INC - BTI WILL BE RESPONSIBLE FOR INITIATING AND MANAGING CLINICAL PROGRAM.BIOXCEL THERAPEUTICS INC - MERCK KGAA, DARMSTADT, GERMANY AND PFIZER SUPPLYING AVELUMAB AND NEKTAR SUPPLYING NKTR-214..BIOXCEL THERAPEUTICS INC - BTI AND NEKTAR WILL EQUALLY SHARE ALL DEVELOPMENT COSTS.  Full Article

Pfizer Receives Positive CHMP Opinion For Lorviqua
Friday, 1 Mar 2019 

March 1 (Reuters) - Pfizer Inc ::PFIZER RECEIVES POSITIVE CHMP OPINION FOR LORVIQUA® (LORLATINIB) FOR CERTAIN ADULT PATIENTS WITH PREVIOUSLY-TREATED ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER.PFIZER INC - CHMP'S OPINION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION (EC), WITH A DECISION EXPECTED IN COMING MONTHS.  Full Article

EU Medicines Agency Recommends Approval Of Pfizer's Vizimpro, Bristol-Myers' Reyataz
Friday, 1 Feb 2019 

Feb 1 (Reuters) - EMA's CHMP::EU MEDICINES AGENCY RECOMMENDATIONS FOR JAN 2019.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF PFIZER’S LUNG CANCER DRUG VIZIMPRO.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF BRISTOL-MYERS SQUIBB’S HIV DRUG REYATAZ.  Full Article

UPDATE 5-Biogen scraps two Alzheimer drug trials, wipes $18 bln from market value

CHICAGO/TOKYO, March 21 Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday.